Kovitz Investment Group Partners LLC Has $310,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Kovitz Investment Group Partners LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 21.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,728 shares of the medical research company’s stock after purchasing an additional 310 shares during the period. Kovitz Investment Group Partners LLC’s holdings in IQVIA were worth $310,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Horizon Investments LLC raised its holdings in shares of IQVIA by 3.3% in the third quarter. Horizon Investments LLC now owns 1,418 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 45 shares during the last quarter. RE Advisers Corp increased its holdings in IQVIA by 53.3% during the third quarter. RE Advisers Corp now owns 141 shares of the medical research company’s stock worth $34,000 after buying an additional 49 shares during the last quarter. FDx Advisors Inc. increased its holdings in IQVIA by 0.8% during the fourth quarter. FDx Advisors Inc. now owns 6,382 shares of the medical research company’s stock worth $1,801,000 after buying an additional 49 shares during the last quarter. Vestmark Advisory Solutions Inc. increased its holdings in IQVIA by 5.8% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 892 shares of the medical research company’s stock worth $252,000 after buying an additional 49 shares during the last quarter. Finally, Independent Advisor Alliance increased its holdings in IQVIA by 5.0% during the third quarter. Independent Advisor Alliance now owns 1,100 shares of the medical research company’s stock worth $263,000 after buying an additional 52 shares during the last quarter. Institutional investors own 86.66% of the company’s stock.

IQV traded up $2.23 on Tuesday, hitting $236.62. 6,522 shares of the stock were exchanged, compared to its average volume of 1,131,973. IQVIA Holdings Inc. has a 12 month low of $208.61 and a 12 month high of $285.61. The business has a 50-day moving average of $230.75 and a two-hundred day moving average of $247.79. The company has a debt-to-equity ratio of 1.99, a current ratio of 0.91 and a quick ratio of 0.91. The firm has a market capitalization of $45.17 billion, a price-to-earnings ratio of 47.38, a PEG ratio of 2.10 and a beta of 1.46.

IQVIA (NYSE:IQV – Get Rating) last posted its quarterly earnings data on Tuesday, February 15th. The medical research company reported $2.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.25 by $0.17. IQVIA had a net margin of 6.96% and a return on equity of 27.51%. The business had revenue of $3.64 billion during the quarter, compared to analysts’ expectations of $3.61 billion. During the same quarter in the prior year, the business posted $2.00 earnings per share. IQVIA’s revenue was up 10.2% compared to the same quarter last year. Equities research analysts expect that IQVIA Holdings Inc. will post 9.43 earnings per share for the current fiscal year.

IQV has been the topic of a number of recent analyst reports. UBS Group lowered their target price on shares of IQVIA from $310.00 to $290.00 in a report on Wednesday, February 16th. StockNews.com initiated coverage on shares of IQVIA in a report on Thursday, March 31st. They set a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on shares of IQVIA from $250.00 to $290.00 and gave the stock a “buy” rating in a report on Tuesday, April 12th. Mizuho decreased their price objective on shares of IQVIA from $300.00 to $270.00 and set a “buy” rating on the stock in a report on Monday, March 7th. Finally, Morgan Stanley decreased their price objective on shares of IQVIA from $290.00 to $280.00 and set an “overweight” rating on the stock in a report on Wednesday, February 16th. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of “Buy” and an average price target of $280.29.

IQVIA Company Profile (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

See Also